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Abstract
Background—The recommendation by the American Society of Transplantation for annual 
trivalent inactivated influenza vaccination greater than 3 to 6 months post-kidney transplantation 
provides a unique opportunity to test the in vivo impact of immunosuppression on recall T- and B-
cell responses to influenza vaccination.
Methods—This study took advantage of recent breakthroughs in the single-cell quantification of 
human peripheral blood B-cell responses to prospectively evaluate both B- and T-cell responses to 
the seasonal (2010 and 2011) influenza vaccine in 23 stable renal transplant recipients and 22 
healthy controls.
Results and Conclusion—The results demonstrate that the early B-cell response to influenza 
vaccination, quantified by the frequency of influenza-specific antibody-secreting cells (ASC) in 
peripheral blood, was significantly reduced in stable transplant recipients compared to healthy 
controls. The magnitude of the seroresponse and the rate of sero-conversion were also blunted. 
The influenza-specific interferon-gamma (IFNγ) T-cell response was significantly reduced in 
transplant recipients; however, there was no correlation between the magnitude of the influenza-
specific IgG ASC and IFNγ responses. The induction of memory T- and B-cell responses to 
influenza vaccination supports the recommendation to vaccinate while the blunted responses 
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demonstrate the efficacy of immunosuppression in controlling memory responses individual 
transplant recipients.
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Following numerous reports in the past decade confirming that the annual trivalent 
inactivated influenza vaccine is safe and generally well tolerated in transplant patients, there 
has been a greater adoption of the Centers for Disease Control and Prevention (CDC) 
influenza vaccination guidelines to vaccinate solid-organ transplant recipients (1–6). 
Nonetheless, concerns regarding the efficacy of vaccination in transplant recipients on 
chronic immunosuppression (7–13) as well as the possibility that the vaccination could 
trigger rejection episodes (14–16) are most frequently cited as reasons to not vaccinate (4). 
Vaccine responses are assessed by hemagglutination-inhibition or microneutralization 
antibody titers post-immunization (17, 18), and there is considerable variability in the 
reported overall seroconversion rates in transplant recipients, which could be a result of 
heterogeneity in the individual response to the vaccine, immunosuppression regimen, or both 
(3, 13, 19–22).
It has become clear that the administration of the trivalent inactivated influenza vaccine in 
healthy volunteers triggers a rapid activation of memory influenza-specific B cells, leading 
to their proliferation and differentiation into plasmablasts within secondary lymphoid organs 
(23, 24). After 6 to 8 days, a large number of CD19+ CD3−, CD20low CD27highCD38high 
plasmablasts are detected in the blood by flow cytometry, as well as influenza-specific ASCs 
by ELISPOT assay (24–26). These plasmablasts emerge rapidly from memory B cells and 
contribute to the pool of long-lived plasma cells that locate in the bone marrow (24). We 
hypothesize that these newer approaches for quantifying the recall B-cell response at a 
single-cell resolution allow for a more direct quantification of the memory B-cell response to 
influenza vaccination and complements routine assessments of neutralizing antibody titers 
(27). Furthermore, the easy quantification of this response to influenza vaccination will 
allow an assessment of the extent to which standard immunosuppression inhibits a recall B-
cell response in individual renal transplant recipients (24).
In this study, the B cell and antibody responses to influenza vaccine was quantified in stable 
kidney transplant recipients and matched healthy controls. Because the influenza vaccine 
also induces T-cell responses that have been shown to contribute to viral clearance (28–30), 
we also assessed the magnitude of the recall influenza-specific T-cell responses. 
Collectively, these studies quantify the magnitude of the cellular and humoral response to 
influenza vaccination in stable kidney transplant recipients, and at the same time provide 
insights into the efficacy of immunosuppression in blunting these responses.
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The demographic data of study subjects that received the trivalent inactivated influenza 
vaccine are summarized in Table 1. Because the time posttransplantation can affect the level 
of immunosuppression and immune responses blunted in patients with poor kidney function, 
the transplant study population was restricted to patients greater than or equal to 6 (6–72) 
months posttransplantation, with serum creatinine less than or equal to 1.5 mg/dL, on 
standard triple immunosuppression with no escalation in immunosuppression in the 6 
months before vaccination. The control group was matched in race, age, and gender, but had 
significantly lower serum creatinine levels and higher glomerular filtration rates. Transplant 
and control subjects received a single dose of the 2010 or 2011 inactivated influenza 
vaccine, which were identical in both years.
Reduced Influenza-Specific B-Cell Responses in Stable Kidney Transplant Recipients
The plasmablast response was first evaluated, identified as CD3−CD19+CD27+CD38+ cells, 
in the peripheral blood of transplant and controls at 0, 7, and 14 or 28 days after influenza 
vaccination (Fig. 1A). Overall, the percentage of plasmablasts on day 0 in transplant 
recipients was significantly lower than controls (P=0.001). Both groups had modestly 
increased plasmablast percentages on day 7 post-immunization, consistent with previous 
observations (24), although these increases were not significantly different from day 0 or day 
14 (Fig. 1D). The percentage of plasmablasts on day 7 in transplant recipients was 
significantly lower than controls (P=0.05), and the median increase in the percentage of 
plasmablasts at day 7 post-vaccination tended to be lower in the transplant group compared 
to the control (0.09% vs. 0.26%); however, this difference was not significant (P>0.05). 
Possible explanations for these observations could be variability and the lack of specificity 
of the measured plasmablast response, thus the influenza-specific ASC IgG response was 
further evaluated using an ELISPOT assay (Fig. 2).
Peak ASC response in peripheral blood mononuclear cells (PBMC) was detected on day 7 
post-vaccination and returned to baseline by day 14 or 28 post-vaccination (Fig. 2; data not 
shown). Statistically significant increases in influenza-specific ASC IgG response was 
observed in both transplant and control cohorts on day 7 post-vaccination, with a median 
increase of 1.9/250,000 PBMC in transplant recipients and a median increase of 
17.3/250,000 PBMC in the controls (Fig. 2A–C). The magnitude of influenza-specific ASC 
response from day 0 to 7 post-vaccination in the transplant recipients was significantly 
reduced 9.1-fold compared to the controls (P=0.0006), thus demonstrating the extent 
maintenance immunosuppression inhibits the rapid generation of ASC from pre-existing 
memory B cells. The heterogeneity of the ASC responses is noteworthy with 6.3% of 
transplant recipients having responses above the median and 32% having responses above 
the first quartile of controls.
Reduced Influenza-Specific Antibody Responses in Stable Kidney Transplant Recipients
The cellular ASC response has been shown to predict the circulating antibody response, thus 
we next assessed the serum antibody responses to influenza vaccination (24). Day 0 and day 
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28 post-vaccination serum samples were tested against the all three viral strains used in the 
vaccine in an ELISA assay, and the fold increase in titers was determined (Fig. 3). 
Consistent with the ASC data, the fold increase in influenza-specific IgG titers was 
significantly reduced in the transplant compared to control populations, with a 5-fold median 
increase in the controls and a 1-fold median increase in the transplant population (Fig. 3A). 
The percentage of individuals that achieved greater than or equal to a 4-fold increase in 
antibody titer from baseline was also significantly reduced in transplant recipients (46.2%) 
compared to the controls (77.8%) (Fig. 3b). Finally, microneutralization assays were 
performed with a cohort of sera from patients and controls vaccinated in 2011, and a trend 
towards reduced percentages of seroconversion (≥4-fold increase between pre-and post-
vaccination titers) to A/California/7/09-like (H1N1) virus was observed in the transplant 
group (Fig. 3C). This observation could reflect the superior immunogenicity of the A/
California/7/09-like (H1N1) virus or a greater memory to this virus. No differences were 
observed with the standard HAI assay (data not shown), likely reflecting the small sample 
size as well as the superior sensitivity of the micro-neutralization assay.
Reduced Influenza-Specific IFNγ Response in Stable Kidney Transplant Recipients
A major component of cell-mediated immunity to influenza vaccine comprises memory 
CD4+Th1 and CD8+ T cells, which secrete IFNγ and TNF> upon re-exposure to influenza 
vaccination (31, 32). In this study, T-cell responses to influenza vaccine were quantified with 
an IFNγ ELISPOT assay using peripheral blood collected at day 0 and 7 or 14 post-
vaccination. Controls and transplant recipients had comparably low frequencies of influenza-
specific, IFNγ-producing cells in the peripheral blood before vaccination and was 
significantly increased on day 7 or 14 (Fig. 4A,B). The frequency of influenza-specific 
IFNγ-producing cells significantly increased from a median of 2.3 to 46/250,000 PBMC and 
from 1.3 to 5/250,000 PBMC for the controls and transplant recipients, respectively (Fig. 
4C). The overall response was significantly reduced in transplant recipients compared to 
healthy controls, with controls exhibiting a median 44.7-fold increase and transplant 
recipients a 4.0-fold increase in the frequency of IFNγ-producing cells. A considerable 
variation was noted in the IFNγ response in transplant recipients, with 18% having responses 
above the median and 47% above the first quartile of controls. There was a lack of 
correlation between the magnitude of the influenza-specific IFNγ and the ASC or antibody 
response in individual transplant patients (Fig. 4D, data not shown), arguing for an 
independent suppression of influenza-specific T- and B-cell responses by maintenance 
immunosuppression.
DISCUSSION
In vitro experiments with human PBMC can provide insights into the potential impact of 
immunosuppression on the human immune response; however, it is challenging to 
extrapolate to the in vivo situation. Animal models permit in vivo studies, but species-
specific differences in pharmacokinetics, drug metabolism, and dosing make it difficult to 
accurately extrapolate observations to transplant patients that have considerable genetic 
variation and experience different immunosuppressive regimens. This study took advantage 
of the CDC and the American Society of Transplantation guidelines for influenza 
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vaccination of solid-organ transplant recipients to quantify the induced B- and T-cell 
responses in individual kidney transplant recipients, and comparing their responses to age- 
and race-matched healthy controls. Importantly, because practically every person has been 
exposed to influenza infection or vaccination, the response to influenza vaccination arises 
predominantly from memory B and T cells (24, 33). Thus, this study took advantage of this 
unique opportunity to assess the immunogenicity of influenza vaccine in transplant patients 
and to determine the extent to which maintenance immunosuppression in stable renal 
transplant recipients controls recall B- and T-cell responses.
Calcineurin-based immunosuppression was predicted to be effective at controlling naive and 
memory T-cell responses because of their ability to inhibit the calcium/calcineurin/nuclear 
factor of activated T cells signaling downstream of the T-cell receptor that is necessary for 
the activation of both naive and memory T cells (34, 35). The observation that the influenza-
specific IFNγ T response, which predominantly reflects recent induction from memory T 
cells, was significantly blunted in transplant recipients thus revealed the extent to which 
maintenance immunosuppression blunts the memory T-cell response to influenza 
vaccination—namely ~10-fold reduction in median responses compared to healthy controls. 
Despite significant inhibition, the magnitude of the resulting IFNγ response in individual 
transplant recipients demonstrated wide variability, with some transplant recipients having 
responses that were comparable to that observed in healthy controls. This latter observation 
could be the result of lower efficacy of immunosuppression or individual propensity to be 
high IFNγ responders to the influenza vaccine or both.
The serological response has been used to provide a clinically relevant estimate of vaccine 
immunogenicity and protection from live infection (3, 17, 18). A significant reduction was 
observed in the overall antibody response to the vaccine and seroconversion rates in 
transplant recipients compared to healthy controls. Because increases in antibody responses 
could reflect increases in the frequencies of ASC or antibody secretion by individual ASCs, 
it is reasoned that examination of the plasmablast and ASC responses would provide a more 
direct measure of the vaccine response and the effect of immunosuppression. Furthermore, it 
is currently unclear whether current immunosuppression regimens can inhibit memory B-
cell differentiation into plasma cells. Thus, this study provides, for the first time, evidence 
that maintenance immunosuppression suppressed by 9.1-fold the median influenza-specific 
ASC IgG response in the transplant recipients compared to healthy controls. While this 
study was not designed to determine whether suppression of the ASC response was a result 
of indirect effects on inhibiting T-cell help or to direct inhibition of the memory B cells, the 
lack of correlation between the magnitude of the influenza-specific IFNγ, and ASC and 
antibody responses in individual transplant patients (Fig. 4D), argues for an independent 
suppression of influenza-specific T- and B-cell responses by maintenance 
immunosuppression. Furthermore, there was no correlation between the ASC, or IFNγ 
response, and the time of transplantation, nor was there an effect of type of induction with 
thymoglobulin or IL-2 receptor blockade (data no shown). Finally, it was observed that there 
was no statistically significant correlation between the early plasmablast or influenza-
specific ASC response and the antibody response measured on day 14 or day 28 post-
vaccination. This observation is similar to the report by Nakaya et al. (36) with a larger 
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cohort of healthy controls where only a modest correlation was observed, thus leading the 
authors to conclude that a more robust correlate of immunogenicity is required.
In the transplant study cohort, serum tacrolimus levels at enrollment ranged from 4.7 to 14.7 
ng/mL, but neither the influenza-specific IFNγ nor IgG ASC responses correlated with the 
trough concentrations or dose (data not shown). Previous studies have identified 
mycophenolate mofetil (MMF) to be most effective in reducing serological responses to 
influenza vaccination (3, 7–12). However, MMF doses in the transplant cohort were 
relatively consistent, ranging from 1,000 to 1,500 mg/day, thus future studies involving a 
larger cohort of patients receiving a larger range of doses of MMF will allow us to more 
fully determine whether MMF doses higher than in stable renal transplant recipients 
correlate with the magnitude of the influenza-specific ASC response. Finally, all transplant 
recipients received corticosteroids that have broad effects on non-lymphoid and lymphoid 
cells. Few influenza vaccination studies on the effect of corticosteroids have been reported, 
but the small sample sizes and the use of corticosteroids in combination with other immune-
modulating drugs, as in the case of this study of transplant recipients, make it difficult to 
isolate the effects of corticosteroid on influenza vaccination responses (37).
There are a number of limitations of this study that can be remedied in future studies. First, 
despite the determination of statistically significant reduction in the cellular responses 
between the transplant patients versus the healthy controls, the overall study population is 
small especially for the neutralizing antibody responses measured at day 28 post-
vaccination. Second, the immunological assays quantify detectable responses elicited by the 
vaccination, but they may not be sufficient to prevent influenza infection, and the clinically 
relevant assessment of protection or susceptibility to live influenza infection was not 
investigated. Third, the cellular responses in transplant recipients and healthy controls allow 
for a direct assessment of the effect of triple immunosuppression; however, the study lacks 
power to assess the contribution of each drug. Finally, this study did not assess the 
generation of long-term memory B and T cells as well as plasma cells, nor did it analyze 
patients at early (<6 months) post-transplantation where the levels of immunosuppression 
are considerably higher and more variable.
In summary, this study reveals the extent to which chronic maintenance immunosuppression 
in stable kidney transplant recipients blunts the recall response to influenza vaccine. While 
larger studies are needed for definitive statistical proof of efficacy of vaccination or 
immunosuppression, this study was able to demonstrate that the majority of transplant 
recipients had significantly reduced ASC, IFNγ, and serological responses to influenza 
vaccination. In particular, this study clarifies the extent to which maintenance triple 
immunosuppression blunts memory T-cell responses as well as memory B-cell 
differentiation into ASC in transplant recipients. This study raises the intriguing question of 
whether the magnitude of immune response to influenza vaccine can be extrapolated to 
alloimmune responses and whether individuals with near normal T or B responses, or both, 
to influenza vaccine are inadequately immunosuppressed and more likely to develop 
alloantibodies or succumb to late graft failure. Conversely, it would be equally important to 
test whether individuals with minimal immune responses to influenza vaccine are over-
immunosuppressed and more likely to succumb to opportunistic infections.
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The Institutional Review Board (IRB) of The University of Chicago (Chicago, IL) approved 
this project, and informed consent was obtained from all study participants. The CDC did 
not have access to personal identifiers for the study, thus their IRB review was not required 
under the US federal regulatory guidance. Kidney transplant recipients were recruited from 
the University of Chicago renal transplant clinic from October 2010 thru December 2011 
with the following inclusion criteria: aged 18 to 65 years; greater than or equal to 6 months 
posttransplantation with organs from deceased or living donors; serum creatinine less than or 
equal to 1.5 mg/dL; on triple immunosuppression regimen consisting of tacrolimus (1–12 
mg/day), steroids (5 mg/day), and an antiproliferative agent, MMF (1,000–1,500 mg/day) or 
mycophenolate sodium (720–1,440 mg/day); and without escalation in immunosuppression 
regimen for any reason in the previous 6-month period. One patient received sirolumus (1 
mg/day) instead of tacrolimus. All patients received thymoglobulin (61%) or basiliximab-
daclizumab (39%) as induction therapy. Estimated glomerular filtration rate was determined 
using the four-variable Modification of Diet in Renal Disease Study equation. Healthy 
controls, aged 18 to 65 years, were recruited during the same period and included family 
members of enrolled transplant recipients and individuals from the University of Chicago 
healthcare community. Exclusion criteria for both groups included previous receipt of the 
2010 or 2011 influenza vaccine in that same year, known anaphylactic reactions to eggs, or 
acute febrile illness in the week before enrollment.
Enrolled subjects participated in a total of three study visits. The first visit consisted of 
informed consent, demographic and clinical data collection, blood collection, and 
administration of the influenza vaccine available at the University of Chicago medical center 
(2010–2011: FLUVIRIN—Novartis Vaccines and Diagnostics Limited, Liverpool, UK; 
2011–2012: Fluzone—Sanofi Pasteur, Swiftwater, PA, USA). The influenza vaccine 
composition was identical for both years, comprising A/California/7/2009 (H1N1)-like, A/
Perth/16/2009-like (H3N2), and B/Brisbane/60/2008-like viruses. In follow-up visits on 
days 7 and 14 (for 2010) or 28 (for 2011), post-vaccination blood and serum samples were 
collected. There were no significant side effects of the influenza vaccine, beyond what was 
anticipated such as sore arm and low-grade fever, observed in the transplant patients or 
controls.
Cell and Serum Isolation
Peripheral blood mononuclear cells were enriched using Rosette Sep human total 
lymphocyte enrichment cocktail (Stemcell Technologies) and lymphocyte separation media 
(Mediatech). Cells were resuspended in complete media (RPMI-1640+10% FCS+penicillin, 
streptomycin, L-glutamine, HEPES buffer [1 M], and 50 μM β-mercaptoethanol). Cells were 
used on the same day of collection. Serum was isolated from fresh blood and frozen at 
−80°C for later use.
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Antibody Secreting Cell Responses by Flow Cytometry
Peripheral blood mononuclear cells were incubated with the following antibodies: anti-CD3 
FITC, anti-CD19 PE-Cy7, anti-CD27 PE (Invitrogen) as well as anti-CD38 AF 647 and anti-
CD20 PacBlue (Biolegend). Antibody secreting cells were gated as CD19+ CD3−, CD20low 
and then sub-gated as CD27highCD38high (LSRII-Blue), and data was analyzed using FlowJo 
software.
ELISPOT and ELISA
To enumerate the number of IgG-secreting or IFNγ-producing influenza-specific antibody 
secreting cells, 96-well ELISPOT filter plates (Millipore, MAHA N4510) were coated with 
either the influenza vaccine (FLUVIRIN or Fluzone) or mouse anti-human IFNγ (Mabtech). 
PBMC in a dilution series was incubated for 12 to 14 hours for ASC and 48 hours for IFNγ 
ELISPOT assays. Stimulation with the influenza vaccine or phytohemagglutinin (Sigma) 
was included for the IFNγ ELISPOT assay. To visualize spots, goat anti-human IgG (Fcγ) 
biotin, mouse anti-human IFNγ biotin (Mabtech), and avidin-horseradish peroxidase (HRP) 
conjugate (BD Pharmingen) and 3 amino-9 ethylcarbozole substrate (Sigma) were used, and 
spots were enumerated using an automated ELISPOT counter (Cellular Technologies Ltd.).
Antibody responses were measured using influenza-specific ELISA performed similar to the 
ELISPOT assay. Briefly, plates were coated with the influenza vaccine, and serum was 
added in serial dilution and detected with anti-human IgG biotin, avidin-HRP conjugate, and 
tetramethylbenzidine substrate (eBioscience). Absorbencies were measured at OD450 on a 
microplate reader (Invitrogen).
Serological Assays
The microneutralization assay was performed at the CDC as previously described (38, 39). 
Sera were heat inactivated at 56°C for 30 minutes and tested in serial 2-fold dilutions 
starting at a 1:10 dilution. MN titers were expressed as the reciprocal of the highest dilution 
of serum that gave greater than or equal to 50% neutralization. Sera that yielded titers less 
than the starting dilution of 1:10 were reported as a titer of 5.
Statistics
Statistical analyses (described in context) were performed using GraphPad Prism. Mann-
Whitney U test was used for continuous variables with non-normal distribution, Wilcoxon 
signed-rank test was used for paired data, non-parametric Spearman test was used to 
determine correlation, and unpaired t test or two-way ANOVA with a Bonferroni post hoc 
test for non-continuous unpaired data.
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Total plasmablast response to influenza vaccination. A, gating strategy for the plasmablast 
(CD3−CD19+ CD27+CD38+) response to influenza vaccination. B, data are presented as 
percentage of total CD3−CD19+ B cells, on the indicated days post-immunization for 
healthy controls (N=21) and transplant recipients (N=22). Bars indicate the median, and 
significant differences were determined by Kruskal-Wallis test.
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Influenza-specific ASC response to influenza vaccination. A, quantification of the frequency 
of influenza-specific IgG secreting cells (ASC) by ELISPOT. Data are presented as the 
frequency of influenza-specific ASC on day 0 and 7 for controls (B) or transplant recipients 
(C), or the increase (day 7 subtracted from day 0 baseline) (D). Each symbol represents data 
from an individual (controls N=21; transplant recipients N=22). Bars represent the median, 
and statistical significance was determined by Wilcoxon signed rank test (B and C) or 
Mann-Whitney test (D).
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Anti-influenza IgG seroresponse and seroconversion following influenza vaccination. A, 
quantification of the anti-influenza IgG seroresponse by ELISA. Data represent the increase 
in the geometric mean titers (GMT; bar indicates median increase) from day 0 to day 14/28, 
with transplant patients (N=13) exhibiting significantly reduced responses compared to 
healthy controls (N=18). B, the response rate (%), which refers to the percentage of subjects 
with a 4-fold increase in titers on day 14/28 post-vaccination, was also significantly different 
between the two groups. C, anti-influenza titers were quantified by microneutralization 
(MN) assays to A/California/7/09-like (H1N1) (A/Calif), A/Perth/16/2009-like (H3N2) (A/
Perth), and B/Brisbane/60/2008-like (B/Brisb) influenza virus. Data are presented as the 
median fold increase and percent seroconversion, which is defined as the percentage with a 
4-fold increase in titers at day 28 post-vaccination. Data are from transplant patients (N=6) 
or controls (N=12) vaccinated in 2011. Statistical significance was determined by Mann-
Whitney test (A) or unpaired t test (B) or two-way ANOVA with a Bonferroni post hoc test 
(C).
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Quantification of the anti-influenza IFNγ response by ELISPOT assays on day 0 and days 7 
or 14 post-influenza vaccination. Both controls (A; N=21) and transplant patients (B; N=17) 
had a significant response to influenza vaccine; however, the magnitude of the response was 
significantly decreased in transplant recipients (C). Data are presented as medians and 
statistical significance was determined by Wilcoxon paired rank test (A and B) and Mann-
Whitney test (C). Statistically significant correlation between the influenza-specific IFNγ 
and IgG response (measured by ELISPOT) in healthy controls (right), but no significant 
correlation in transplant recipients (left).
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TABLE 1
Demographics of study population
Transplant (n=22)a Control (n=21)a
Age, yr 43.6±11.1 45.0±12.6 P>0.05
Male 7 6
Female 15 15
African American 56% 50%
Hispanic 17% 14%
Other 26% 36%
Creatinine, mg/dL 1.12±0.14 0.85±0.18 P<0.05
GFR, mL/min/1.73 m2 57.7±7.5 82.7±12.0 P<0.05
Time from transplant, mo 28±20 N/A
Type of graft, %
 Cadaveric 41%
 Living related 27%
 Living unrelated 32% N/A
Percent with 2nd transplant (%) 27% N/A
Immunosuppression dose
 Tacrolimus <3 mg/d 36%
 Tacrolimus 3–6 mg/d 32%
 Tacrolimus >6 mg/d 33%
 Tacrolimus trough, ng/mL 6.8±2.4 N/A
Induction therapy
 Basiliximab/daclizumab 39%
 Thymoglobulin 61% N/A






 Unknown 14% N/A
a
Values are given as mean±SD.
FSGS, focal segmental glomerulosclerosis; PCKD, polycystic kidney disease; SLE, systemic lupus erythematosus.
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